Avoid common mistakes on your manuscript.
1 Erratum to: Drugs (2015) 75:75–82 DOI 10.1007/s40265-014-0329-y
The author has alerted us to the following errors:
Page 79, column 2, paragraph 1, line 7.
The sentence that previously read:
‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four with prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’
should read:
‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four without prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’
Page 80, figure 4 legend, lines 5 and 6.
The figure legend that previously read:
‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in ≥10 % of patients (n = 46) in the phase 2 portion of a phase 1–2 study [18]. ALP alanine phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CPK creatinine phosphokinase.’
should read:
‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in ≥10 % of patients (n = 46) in the phase 2 portion of a phase 1–2 study [18]. ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CPK creatine phosphokinase.’
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-014-0329-y.
Rights and permissions
About this article
Cite this article
McKeage, K. Erratum to: Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer. Drugs 75, 241 (2015). https://doi.org/10.1007/s40265-015-0346-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-015-0346-5